Changes in Beneficial Ownership · 4/A
Q32 Bio Inc.
QTTBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4/A
ownership.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-06-12
- Original submission
- 2026-06-16
- Issuer
- Q32 Bio Inc.
- Issuer CIK
- 0001661998
- Trading symbol
- QTTB
Reporting owner 1
- Name
- TZIANABOS ARTHUR
- Reporting owner CIK
- 0001586226
- Relationship
- Director
- Address
- Q32 BIO INC., 830 WINTER STREET, WALTHAM, MA, 02451
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 12.64 | 2026-06-12 | A · Form 4 | 10,826[F1] | A | 0 | [F2] | 2036-06-11 | Common Stock | 10,826[F1] | 10,826[F1] | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.↩ 1↩ 2↩ 3
- F2
- The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.↩ 1
Signature 1
- Signed
- /s/ Eric Bell, Attorney-in-Fact
- Date
- 2026-07-21
Company context
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.